update on kawasaki disease june 7 th, 2010 aaron s. miller, md, msph division of hospitalist...
TRANSCRIPT
Update on Kawasaki Update on Kawasaki DiseaseDisease
June 7June 7thth, 2010, 2010Aaron S. Miller, MD, MSPHAaron S. Miller, MD, MSPH
Division of Hospitalist MedicineDivision of Hospitalist MedicineSt. Louis Children’s HospitalSt. Louis Children’s Hospital
Update on Kawasaki DiseaseUpdate on Kawasaki Disease
Definition / pathologyDefinition / pathology HistoryHistory Epidemiology and search for etiologyEpidemiology and search for etiology Differential diagnosis Differential diagnosis Clinical findingsClinical findings EvaluationEvaluation TreatmentTreatment Follow-upFollow-up
Kawasaki Disease (KD):Kawasaki Disease (KD):
An acute, self-limited disease that An acute, self-limited disease that manifests as a multisystemic medium manifests as a multisystemic medium vessel vasculitis that is largely seen in vessel vasculitis that is largely seen in
children under 5 years of age children under 5 years of age
PathologyPathology
Systemic vasculitis affecting Systemic vasculitis affecting any medium sized vessels any medium sized vessels (e.g. coronary, celiac, (e.g. coronary, celiac, mesenteric)mesenteric)
Vessel walls infiltrated with Vessel walls infiltrated with neutrophils, mononuclear neutrophils, mononuclear cells and lymphocytescells and lymphocytes
Endothelial cell swellingEndothelial cell swelling Destruction of internal elastic Destruction of internal elastic
lamina gives way to vessel lamina gives way to vessel dilatation and aneurysm dilatation and aneurysm formationformation
HistoryHistory Dr. Tomisaku Kawasaki first described Dr. Tomisaku Kawasaki first described
the clinical features in children in Japan the clinical features in children in Japan in late 1960’s and called it in late 1960’s and called it mucocutaneous lymph node syndromemucocutaneous lymph node syndrome
1970’s coronary sequelae became 1970’s coronary sequelae became apparent when children who had the apparent when children who had the disease had sudden death and were disease had sudden death and were found to have coronary artery found to have coronary artery aneurysms with thrombosis and aneurysms with thrombosis and myocardial infarctionmyocardial infarction
Burns JC et al. Kawasaki Disease: A Brief History. Pediatrics. Burns JC et al. Kawasaki Disease: A Brief History. Pediatrics.
2000;106(2): E27.2000;106(2): E27.
Dr. Kawasaki’s original notes on Dr. Kawasaki’s original notes on first KD patientfirst KD patient
Etiology of KDEtiology of KD Streptococcal superantigensStreptococcal superantigens Scald injuriesScald injuries Mycoplasma pneumoniaeMycoplasma pneumoniae Varicella zosterVaricella zoster PollenPollen Neisseria meningitidisNeisseria meningitidis Chlamydia pneumoniaeChlamydia pneumoniae MeaslesMeasles Staphylococcal toxinStaphylococcal toxin Parvovirus B19Parvovirus B19 HHV-6HHV-6
Rug shampooingRug shampooing Proprionibacterium acnesProprionibacterium acnes House dust mitesHouse dust mites Living near bodies of waterLiving near bodies of water Humidifier useHumidifier use Coxiella burnetiiCoxiella burnetii AdenovirusAdenovirus RetrovirusRetrovirus Pseudomonas aeruginosaPseudomonas aeruginosa Parainfluenza virusParainfluenza virus Ehrlichia canisEhrlichia canis ““New Haven” CoronavirusNew Haven” Coronavirus
EpidemiologyEpidemiology
Most common in Japan and in children of Most common in Japan and in children of Japanese descentJapanese descent
Asian > African American > Hispanic > Asian > African American > Hispanic > CaucasianCaucasian
Median age = 2 years (>80% of patients < 5 Median age = 2 years (>80% of patients < 5 years)years)
Most common cause of acquired childhood heart Most common cause of acquired childhood heart disease in the developed worlddisease in the developed world
Holman RC et al. Kawasaki syndrome hospitalizations in the United States, 1997-2000. Holman RC et al. Kawasaki syndrome hospitalizations in the United States, 1997-2000. Pediatrics. 2003;112:495–501.Pediatrics. 2003;112:495–501.
Genetic componentGenetic component
Individuals of Japanese origin, no matter Individuals of Japanese origin, no matter which country they live in, are more likely which country they live in, are more likely to acquire Kawasaki diseaseto acquire Kawasaki disease
Siblings of children with Kawasaki’s Siblings of children with Kawasaki’s disease are more likely than other disease are more likely than other neighborhood children to develop the neighborhood children to develop the illness illness
Epidemiological data suggests Epidemiological data suggests an infectious etiologyan infectious etiology
Seasonal peak in winter and spring monthsSeasonal peak in winter and spring months Epidemics often with a clear epicenterEpidemics often with a clear epicenter Peak incidence in toddlers with rare cases less than Peak incidence in toddlers with rare cases less than
3 months and in adults 3 months and in adults Similar clinical presentation to adenovirus and Similar clinical presentation to adenovirus and
scarlet feverscarlet fever Self limited nature of the illnessSelf limited nature of the illness
Classic Clinical CriteriaClassic Clinical Criteria
Fever for Fever for >> 5 days 5 days >> 4 of the 5 principle features 4 of the 5 principle features Exclusion of diseases with similar findingsExclusion of diseases with similar findings
Rules that have expanded the Rules that have expanded the clinical criteriaclinical criteria
Kawasaki’s Disease may be diagnosed if:Kawasaki’s Disease may be diagnosed if: If fever and If fever and >> 4 principle features are present, 4 principle features are present,
the diagnosis of KD can be made on day 4 of the diagnosis of KD can be made on day 4 of illnessillness
If fever If fever >> 5 days, < 4 principle features are 5 days, < 4 principle features are present AND ECHO evidence of coronary artery present AND ECHO evidence of coronary artery diseasedisease
KD should be considered in any infant < 6 KD should be considered in any infant < 6 months of age with prolonged fever, even if no months of age with prolonged fever, even if no principle features are presentprinciple features are present
Differential DiagnosisDifferential Diagnosis Viral infection (adenovirus, enterovirus, EBV, HHV-6, Viral infection (adenovirus, enterovirus, EBV, HHV-6,
measles)measles) Drug hypersensitivity reactionDrug hypersensitivity reaction Stevens-Johnson syndrome / Toxic epidermal necrolysisStevens-Johnson syndrome / Toxic epidermal necrolysis Scarlet feverScarlet fever Ehrlichiosis / Rocky Mountain Spotted FeverEhrlichiosis / Rocky Mountain Spotted Fever Staphylococcal scalded skin syndromeStaphylococcal scalded skin syndrome Toxic shock syndromeToxic shock syndrome Juvenile rheumatoid arthritisJuvenile rheumatoid arthritis LeptospirosisLeptospirosis Mercury hypersensitivity reaction (acrodynia)Mercury hypersensitivity reaction (acrodynia)
FeverFever
Most common manifestation of KDMost common manifestation of KD High-spiking High-spiking Peak temperatures >39Peak temperatures >39°° Without therapy, fever lasts a mean of 11 days Without therapy, fever lasts a mean of 11 days
but up to 4 weeksbut up to 4 weeks Usually resolves within 2 days of appropriate Usually resolves within 2 days of appropriate
therapytherapy
Bulbar ConjunctivitisBulbar Conjunctivitis
Appears shortly after the Appears shortly after the onset of fever and is seen onset of fever and is seen in 90% of patientsin 90% of patients
Typically spares the Typically spares the limbus limbus
Painless and non-Painless and non-exudativeexudative
Mild acute iridocyclitis or Mild acute iridocyclitis or anterior uveitis may be anterior uveitis may be seen on slit lamp examseen on slit lamp exam
http://www.rch.org.au/clinicalguide
http://www.mars.dti.ne.jp/~maachan/Kawasaki.html
Polymorphous ExanthemPolymorphous Exanthem
Rash usually appears Rash usually appears within 5 days of feverwithin 5 days of fever
Rash most commonly a Rash most commonly a diffuse maculopapular diffuse maculopapular eruption, but may be eruption, but may be urticarial, scarlatiniform, urticarial, scarlatiniform, erythroderma, erythema-erythroderma, erythema-multiforme-like, or multiforme-like, or micropustularmicropustular
Rash usually involves the Rash usually involves the trunk and extremities and trunk and extremities and is accentuated in the is accentuated in the perineal regionperineal region
www.chennaionline.com/.../ kawasaki-disease.jpghttp://www.emedicine.com/MED/topic1223.htm
Changes in the Lips and Oral CavityChanges in the Lips and Oral Cavity
Erythema, dryness, Erythema, dryness, fissuring, peeling, fissuring, peeling, cracking and bleeding cracking and bleeding of the lipsof the lips
““Strawberry tongue” Strawberry tongue” with erythema and with erythema and prominent papillaeprominent papillae
Diffuse erythema of Diffuse erythema of the oral mucosathe oral mucosa
http://www.healthcentral.com/mhc/top/003097.cfm
Cervical LymphadenopathyCervical Lymphadenopathy
Unilateral and Unilateral and confined to the confined to the anterior cervical anterior cervical triangletriangle
>> 1.5 cm in diameter 1.5 cm in diameter Firm and non-Firm and non-
fluctuantfluctuant
Council on Cardiovascular Disease in the Young. Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease. American Heart Association. Diagnostic guidelines for Kawasaki disease. Circulation. 2001;103(2):335-6.
Extremity ChangesExtremity Changes
Acute:Acute: Erythema of the palms Erythema of the palms
and soles and/or and soles and/or edema of the hands edema of the hands and feetand feet
Subacute (2-3 Subacute (2-3 weeks):weeks): Desquamation of the Desquamation of the
fingers and toes (70-fingers and toes (70-98% of children)98% of children)
CNS: Extreme irritability, aseptic meningitis,
GU: Urethritis
Hepatic: Hepatic dysfunction, hydrops of the gallbladder
GI: Vomiting, diarrhea, abdominal pain
CVS: Myocarditis, pericarditis, valvular dysfunction, CHF, coronary artery abnormalities
PERIPHERAL VASCULAR: Raynaud’s phenomenon, peripheral gangrene
SKIN: Desquamating rash in the groin
MUSCULOSKELETAL: Arthritis/arthralgia
EYE: Anterior uveitis
Additional Clinical FindingsAdditional Clinical Findings
PULMONARY: Dyspnea, tachypnea, hypoxia, cough, pulmonary infiltrate on CXR
Laboratory Findings in KDLaboratory Findings in KD
↑↑ WBC WBC ↑↑ CRPCRP ↑↑ ESRESR ↑↑ Platelets Platelets (after week one)(after week one)
↑↑ AST, ALT, GGTAST, ALT, GGT ↓ ↓ Hgb/HctHgb/Hct ↓↓ AlbuminAlbumin ↓↓ NaNa
Sterile pyuriaSterile pyuria CSF pleocytosisCSF pleocytosis Leukocytosis in the Leukocytosis in the
synovial fluidsynovial fluid elevated plasma lipidselevated plasma lipids
Coronary Artery Disease in KDCoronary Artery Disease in KD
~15% to 25% of untreated patients develop ~15% to 25% of untreated patients develop coronary artery abnormalitiescoronary artery abnormalities
~5% of children treated with IVIG within 10 days ~5% of children treated with IVIG within 10 days develop coronary artery abnormalitiesdevelop coronary artery abnormalities
1% of children treated with IVIG within 10 days 1% of children treated with IVIG within 10 days develop giant aneurysmsdevelop giant aneurysms
Coronary artery aneurysms may lead to ischemic Coronary artery aneurysms may lead to ischemic heart disease, myocardial infarction, or sudden heart disease, myocardial infarction, or sudden deathdeath
Kato H et al. Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of Kato H et al. Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation. 1996; 94: 1379–1385.594 patients. Circulation. 1996; 94: 1379–1385.
Z-scoresZ-scoresof coronary artery diametersof coronary artery diameters
Pediatrics. 2004;114:1708-1733.
What is a positive ECHO?What is a positive ECHO?
Z-score of LAD or RCA of >2.5Z-score of LAD or RCA of >2.5 Coronary aneurysm Coronary aneurysm OR ≥ 3 of the following featuresOR ≥ 3 of the following features
z-score ≥ 2-2.5z-score ≥ 2-2.5 PV brightnessPV brightness lack of taperinglack of tapering low LV functionlow LV function mitral regurgitationmitral regurgitation pericardial effusionpericardial effusion
Evaluation of Suspected Incomplete KD
Supplemental Laboratory Criteria•Albumin < 3 g/dL•Anemia for age•Elevated ALT•Platelets > 450,000 after 7 days of illness•WBC > 15,000/mm3
•UA with > 10 WBC/hpf
Treatment of KDTreatment of KDAspirin Aspirin
Mechanism of action of aspirin:Mechanism of action of aspirin: Anti-inflammatory at high dose (80-100 Anti-inflammatory at high dose (80-100
mg/kg/day divided in 4 doses)mg/kg/day divided in 4 doses) Antiplatelet at low dose (3-5 mg/kg/day)Antiplatelet at low dose (3-5 mg/kg/day)
Aspirin dosingAspirin dosing High dose aspirin should be given acutelyHigh dose aspirin should be given acutely
• Until day 14 of illnessUntil day 14 of illness• AND/ORAND/OR until afebrile for 48-72 hours until afebrile for 48-72 hours
Low dose aspirin is continued as indicated by Low dose aspirin is continued as indicated by risk levelrisk level
Newburger, JW et al. Pediatrics. 2004;114:1708-1733.
Treatment of KDTreatment of KDIntravenous Immune Globulin (IVIG)Intravenous Immune Globulin (IVIG)
First reports of use 1983First reports of use 1983 Dosing: 2 g/kg in a single infusion over 8-12H Dosing: 2 g/kg in a single infusion over 8-12H Timing: Timing:
Should be given within the first 10 days of illnessShould be given within the first 10 days of illness IVIG should be given after day 10 of illness in children IVIG should be given after day 10 of illness in children
with persistent fever or aneurysms and ongoing with persistent fever or aneurysms and ongoing systemic inflammation as manifested by elevated ESR systemic inflammation as manifested by elevated ESR and CRPand CRP
Adverse reactions: chills, rash, aseptic meningitis, Adverse reactions: chills, rash, aseptic meningitis, anaphylaxis, heart failure secondary to fluid overloadanaphylaxis, heart failure secondary to fluid overload
Vaccines: Live virus vaccines should be deferred for 11 Vaccines: Live virus vaccines should be deferred for 11 months after administration of IVIGmonths after administration of IVIG
Newburger, JW et al. Pediatrics. 2004;114:1708-1733.
Corticosteroids plus IVIG as initial Corticosteroids plus IVIG as initial treatment of KDtreatment of KD
The addition of corticosteroids to IVIG and aspirin has shown mixed The addition of corticosteroids to IVIG and aspirin has shown mixed results has from RCTresults has from RCT
2006 Japan study: 178 patients, RCT 2006 Japan study: 178 patients, RCT Prednisolone 2mg/kg/day x 15 days plus IVIG (1g/kg QD x 2 days) plus Prednisolone 2mg/kg/day x 15 days plus IVIG (1g/kg QD x 2 days) plus
aspirin VERSUS IVIG + aspirin aspirin VERSUS IVIG + aspirin Prednisolone group had fewer CA aneurysms (2.2% vs. 11.4%), quicker Prednisolone group had fewer CA aneurysms (2.2% vs. 11.4%), quicker
resolution of fever and were less likely to require IVIG retreatment resolution of fever and were less likely to require IVIG retreatment 2007 US study: 199 patients, RCT 2007 US study: 199 patients, RCT
Methylprednisolone (30mg/kg/day) x 1 plus IVIG (2g/kg x 1) plus aspirin Methylprednisolone (30mg/kg/day) x 1 plus IVIG (2g/kg x 1) plus aspirin VERSUS IVIG and aspirin alone. VERSUS IVIG and aspirin alone.
There were no differences in CA, duration of fever or need for retreatmentThere were no differences in CA, duration of fever or need for retreatment
Inoue Y et al. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome. J Pediatr. 2006;149(3):336-341.
Newburger JW et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med. 2007;356(7):663-75.
Treatment of Refractory KDTreatment of Refractory KD 10 % of patients with KD fail to respond to initial 10 % of patients with KD fail to respond to initial
IVIG (persistent or recurrent for IVIG (persistent or recurrent for >> 36 hours after 36 hours after initial IVIG)initial IVIG)
Retreatment with IVIG (2 g/kg) is recommended Retreatment with IVIG (2 g/kg) is recommended for patients with refractory KDfor patients with refractory KD
Treatment with steroids (methylprednisolone 30 Treatment with steroids (methylprednisolone 30 mg/kg daily for 3 days) should be restricted to mg/kg daily for 3 days) should be restricted to patients who fail to respond to patients who fail to respond to >> 2 doses of IVIG 2 doses of IVIG
Multiple case reports of successful use of Multiple case reports of successful use of infliximab, cyclophosphamide, plasmapheresisinfliximab, cyclophosphamide, plasmapheresis
Burns JC et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr. 2008;153(6):833-8.
Slide 40Slide 40
Follow-up Cardiac Evaluation in Follow-up Cardiac Evaluation in Patients Diagnosed with KDPatients Diagnosed with KD
Follow-up with consulting services (ID and Follow-up with consulting services (ID and cardiology if consulted originally) should cardiology if consulted originally) should be arranged for 2 weeks and 6-8 weeks be arranged for 2 weeks and 6-8 weeks after initial diagnosis.after initial diagnosis.
ECHO should be performed at these visits.ECHO should be performed at these visits. ECHO evaluation may be limited to the ECHO evaluation may be limited to the
coronary arteries.coronary arteries.
PrognosisPrognosis
Rate of recurrence: 3% (in Japan)Rate of recurrence: 3% (in Japan) In hospital mortality: 0.17% (in US)In hospital mortality: 0.17% (in US) Peak mortality: 15-45 days after onset of Peak mortality: 15-45 days after onset of
feverfever Older children with KD may have a higher Older children with KD may have a higher
rate of cardiovascular complications rate of cardiovascular complications related to delayed diagnosisrelated to delayed diagnosis
Natural History of Coronary Artery Natural History of Coronary Artery Lesions in KDLesions in KD
~50% to 67% of coronary artery ~50% to 67% of coronary artery aneurysms resolve within 1-2 yearsaneurysms resolve within 1-2 years
Factors associated with resolution:Factors associated with resolution: Initial size of lesion smallInitial size of lesion small Age < 1 yearAge < 1 year Fusiform rather than saccular aneurysmFusiform rather than saccular aneurysm Aneurysm location in the distal Aneurysm location in the distal
coronary segmentcoronary segment
Thank you to Rachel Orscheln, MD and Thank you to Rachel Orscheln, MD and Jeffery McKinney, MD, PhD for providing Jeffery McKinney, MD, PhD for providing me with the slides I used as a starting me with the slides I used as a starting point for my talkpoint for my talk
Thanks to the SLCH Hospitalist group for Thanks to the SLCH Hospitalist group for providing feedback for this talkproviding feedback for this talk
EndEnd